Login to Your Account

Rolling NDA Set for Next Year

Cell Therapeutics' Pixantrone Hits Endpoint in Phase III Study

By Jennifer Boggs

Wednesday, November 12, 2008
No Abstract

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription